| Bioactivity | Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1]. |
| Invitro | Sirtratumab vedotin (ASG15-ME) 与 SW780 细胞上表达的 SLITRK6 具有高亲和力结合，Kd 为 0.018 nM[1]。Sirtratumab vedotin (10 μg/mL; 1 h) 与 SLITRK6 结合后内化[1]。Sirtratumab vedotin (120 h) 抑制 CHP-212 细胞存活，IC50 为 0.99 nM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Sirtratumab vedotin 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | Sirtratumab vedotin (ASG15-ME; 0.25-5 mg/kg; i.v.; 2x per week for 2 or 3 weeks or single dose) 在小鼠的多个异种移植模型中显示出强大的抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1824663-83-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Morrison K, et al. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016 Jun;15(6):1301-10. |